Study to check safety and effectiveness of cilnidipine, metoprolol succinate and chlorthalidone in Indian hypertensive patients.
Not Applicable
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2019/01/017089
- Lead Sponsor
- Aprica Healthcare Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients willing to provide written informed consent form
2.Male or Female patients aged 18 years and above
3.Essential hypertension which is uncontrolled (defined as systolic BP >= 140 mmHg or diastolic BP >= 90 mmHg ) on dual anti-hypertensive agents
4.Patients treated with cilnidipine, metoprolol succinate and chlorthalidone
Exclusion Criteria
1. Patients receiving any other antihypertensive other than cilnidipine, metoprolol succinate and chlorthalidone
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Reduction in Mean Systolic blood pressure <br/ ><br>2. Reduction in Mean Diastolic blood pressure <br/ ><br>3. Complications <br/ ><br>Timepoint: 1, 3 and 6 months
- Secondary Outcome Measures
Name Time Method 1.Demographic data of study participants <br/ ><br>2.Socioeconomic status of patient <br/ ><br>3. Comorbid conditions <br/ ><br>4.Preferred Dose of cilnidipine, metoprolol succinate and chlorthalidone <br/ ><br>5. Dosage frequency <br/ ><br>6. Administration time <br/ ><br>7. Concomitant medications <br/ ><br>8. Adverse events <br/ ><br>Timepoint: 1, 3 and 6 months